Avella Specialty Pharmacy began as a single pharmacy in Scottsdale, Arizona in 1996. It has since expanded to become one of the fastest-growing healthcare companies in the nation, with locations in eight states and a national distribution center. Through it all, Avella has stayed true to our steadfast vision: facilitating a hands-on, patient and physician focused approach to the dynamic and growing arena of specialty pharmaceuticals.
Avella Specialty Pharmacy launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients. These complimentary, easy-to-use mobile medication guides allow providers to access prescribing information for a wide variety of medications—regardless of manufacturer—all in one place, right from their phone.
Avella Specialty Pharmacy has been selected by pharmaceutical manufacturer AbbVie to dispense Venclexta (venetoclax), the first therapy in its class to win FDA approval. Venclexta is an oral, once-daily drug indicated for use in certain patients with chronic lymphocytic leukemia. The FDA recognized the importance of this new therapy early on, speeding its time to market through a breakthrough therapy designation, priority review status and accelerated approval. Venclexta also received orphan drug designation from the FDA.
Avella has been selected by AstraZeneca to distribute IRESSA® (gefitinib) for a sub-set of patients with metastatic EGFRm positive non-small cell lung cancer (NSCLC). Avella is proud to have been selected to distribute this oncology medication as a first-line treatment for certain lung cancer patients.
Avella, in cooperation with mobile health provider mscripts, conducted a retrospective analysis to assess whether providing HIV patients with access to refill and medication reminders via a mobile app would lead to improved medication adherence.
Avella Specialty Pharmacy has been approved by the National Association of Boards of Pharmacy (NABP) to register a .pharmacy domain name for its website.
Avella has been selected to distribute several oncology medications (Farydak, Nexavar, Stivarga, IBRANCE) as well as a lupus medication (Benlysta). As one of a limited number of specialty pharmacies with access to these medications, Avella’s clinical team is proud to offer such innovative therapies.
Avella Specialty Pharmacy announces a partnership with Sentry Data Systems to help hospitals and health systems manage their participation in the federal 340B drug discount program.
The Accreditation Commission for Health Care (ACHC) recognizes Avella for complying with national standards that facilitate a higher level of performance and quality across all of its clinical and operational processes.
As a designated outsourcing facility, Avella consents to greater federal oversight and adherence to current good manufacturing practices – further demonstrating our commitment to providing the highest level of care and quality for our patients.
Zydelig (idelalisib) is a breakthrough medication used to treat three types of blood cancer. As one of a limited number of specialty pharmacies with access to this oncology medication, Avella’s clinical team is proud to offer such an innovative therapy.
Avella announces that it is prepared to begin distributing Otezla, a new oral therapy to treat active psoriatic arthritis (PsA) in adult patients. Avella is proud to be at the forefront of innovation by providing access to this new medication for psoriatic arthritis.
Avella creates a mobile app and online tool to help patients conveniently manage their prescriptions. The mobile app is one of the first of its kind in the specialty pharmacy industry. Both platforms allow patients to securely request prescription refills, view prescription history and transfer prescriptions, in addition to offering refill reminders and important information about medications.
Avella Specialty Pharmacy recently partnered with researchers at the University of Arizona to look at the effectiveness of behavioral adherence contracts in renal transplant patients. Committed to improved patient outcomes, Avella took part in the National Institute of Health study to assess the effects of a year-long behavioral contract intervention among patients on a specific medication regimen.
Imbruvica (ibrutinib) was initially only indicated to treat patients with mantle cell lymphoma (MCL), but was later FDA approved for patients with chronic lymphocytic leukemia (CLL) as well. Avella is one of only five specialty pharmacies authorized to dispense Imbruvica, and is fully prepared to meet an increase in demand for the medication.
Rebecca Shanahan’s two decades of successful leadership in the healthcare sector, as well as five years of service on Avella’s Board of Directors, make her an excellent choice to succeed founder John Musil, Pharm.D., as CEO of Avella. Her goals as she entered this position were to expand Avella’s clinical pharmacy, patient advocacy, and specialty pharmacy services into new disease categories and via new healthcare partnerships – all areas of success within her first year as CEO.
Avella announces the expansion of its GlowCap® pilot program designed to assist patients in taking their medication on time and on schedule. GlowCap® is a wireless prescription bottle cap equipped with a tool that reminds patients to take their medication through sound and light signals.
Avella Specialty Pharmacy has been chosen by Navitus Health Solutions LLC to provide Synagis® to its managed Medicaid members in Texas and Colorado. The prescription medication is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in infants and children at high risk for severe lung disease from RSV.
Avella is recognized as one of Arizona's top 5 fastest-growing private companies at the Arizona Corporate Excellence (ACE) awards. This sustained growth allows Avella to offer expanded clinical services to customers.
URAC, a Washington, D.C.-based health care accrediting organization that establishes proven standards for the health care industry, recognizes Avella’s dedication to quality, service and patient safety.
Genentech, manufacturer of Tarceva, shifted distribution of the drug to a limited network of select specialty pharmacies to provide appropriate support and guidance for patients receiving this oncology medication. Avella is honored to be chosen as one of these select specialty pharmacies.
Avella began its journey as a compounding pharmacy called “The Apothecary Shops,” but changes its name to reflect the company’s pioneering spirit in the specialty pharmacy industry, as well as to define the transformation the company has made over the previous 16 years.
Primarily focused on infectious diseases, Colorado Pharmacy offers new and exciting customer expanded clinical services under the Avella brand. To complement existing national distribution capabilities, Avella opens in Orlando, FL with future expansion at this location in mind.
Avella receives distribution rights from pharmaceutical manufacturer Pfizer for its new drug Inlyta™ (axitinib), for the treatment of advanced renal cell carcinoma (RCC). The ophthalmic medication inhibits certain receptors that can influence tumor growth and progression of kidney cancer.
Receiving distribution rights for Eylea, an injectable medication that prevents blindness by treating age-related macular degeneration, continues to verify Avella as a market leader in compounded drugs for ophthalmology.
With a prime retail location and capacity for distribution, this location serves patients across the states of Texas, Louisiana, Arkansas and Oklahoma.
The Arizona Corporate Excellence Awards, presented by The Business Journal, honor founder and then-CEO John Musil, Pharm. D., for leading one of Arizona’s largest and fastest-growing private companies. The award recognizes Musil’s innovative approaches, community involvement, dedication to company employees and leadership accomplishments, all of which have been crucial to The Apothecary Shops’ success since its earliest beginnings.
The acquisition of Greater Sacramento Pharmacy facilitates expanding services for patients and offers The Apothecary Shops additional clinical expertise in the key focus area of oncology.
Nexavar was the first oral-cancer therapy that inhibited both tumor and tumor blood vessel growth among patients with advanced kidney and liver cancers. The Apothecary Shops becomes one of only 15 companies nationwide qualified to distribute the drug.
Opening a new corporate headquarters and expanding our call center and national distribution facility to over 25,000-square-feet allows The Apothecary Shops to keep up with the growing base of patients around the nation.
The addition of Afinitor, Nexavar and Caphosol to The Apothecary Shops’ inventory of oncology pharmaceuticals reflects the company’s growing influence in the specialty pharmacy niche.
Avella receives web-site verification approval from LegitScript, a leading consumer advocacy organization whose standards for pharmacy web-site safety and compliance is designed to support health-care consumers and organizations seeking to do business with legitimate online pharmacies.
With a focus in clinical excellence and quality, The Apothecary Shops achieve recognition and accreditation as leaders in the practice of compounding patient medication.
Opening our first location outside of the Southwest establishes our presence as a national pharmacy.
The Apothecary Shops expands its operations outside of Arizona to open a location in Las Vegas, Nevada.
The Apothecary Shops opens a new location in Tucson, Arizona. This is the first time The Apothecary Shops expands outside of the greater Phoenix area.
The Apothecary Shops expands to six community-based pharmacies in metropolitan Phoenix in response to increased demand for its services. These new pharmacies are developed in strategic locations near clinical practices.
Avella Specialty Pharmacy opens its first pharmacy in Scottsdale, Ariz., under former company name (The Apothecary Shops) to address the community’s growing need for expert clinical support and guidance along with breakthrough medications.